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Abstract
Estrogen is a key regulator of normal function of female reproductive system and plays a pivotal role in the development
and progression of breast cancer. Here, we demonstrate that JMJD2B (also known as KDM4B) constitutes a key component
of the estrogen signaling pathway. JMJD2B is expressed in a high proportion of human breast tumors, and that expression
levels significantly correlate with estrogen receptor (ER) positivity. In addition, 17-beta-estradiol (E2) induces JMJD2B
expression in an ERa dependent manner. JMJD2B interacts with ERa and components of the SWI/SNF-B chromatin
remodeling complex. JMJD2B is recruited to ERa target sites, demethylates H3K9me3 and facilitates transcription of ER
responsive genes including MYB, MYC and CCND1. As a consequence, knockdown of JMJD2B severely impairs estrogen-
induced cell proliferation and the tumor formation capacity of breast cancer cells. Furthermore, Jmjd2b-deletion in
mammary epithelial cells exhibits delayed mammary gland development in female mice. Taken together, these findings
suggest an essential role for JMJD2B in the estrogen signaling, and identify JMJD2B as a potential therapeutic target in
breast cancer.
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Introduction
Estrogen plays an important role in normal physiology and
several human diseases including breast cancer. The estrogen
signaling pathway is a reliable therapeutic target for estrogen-
receptor (ER) positive subtype of breast cancer. Understanding of
how ER regulates transcription is key to overcoming resistance to
existing selective ER modulators (SERMs) and identifying non-
SERM targets suitable for novel therapeutic approaches [1].
The biological functions of estrogen are mediated through ER,
which regulates transcription of ER target genes by binding to
estrogen responsive elements (EREs) [2]. Liganded ER undergoes
conformational changes which facilitate cofactor recruitment [3],
and forms multi-subunit protein complexes [4,5,6]. Many of these
co-regulators are enzymes that alter chromatin structure or control
sequential transcriptional reactions [1,7], which include ATP-
dependent chromatin remodeling complexes (SWI/SNF) [8].
However, the molecular mechanisms of how co-regulators are
recruited to the specific genes and how the integrated signals are
transmitted to chromatin are not fully understood.
Genome-wide analyses of chromatin modifications have
revealed a complex landscape of modified histones at transcription
start sites (TSSs), distal regulatory elements and conserved
sequences. In general, methylated H3K4 and H3K36 are
associated with active transcription, whereas methylated H3K9,
H3K27 and H4K20 are associated with gene silencing. H3K4me3
and H3K27me3 signals peak near TSSs. The relative presence of
H3K4me3 and H3K27me3 has been shown to affect promoter
activity [9,10,11,12,13]. H3K9me3 is generally linked to gene
silencing since H3K9me3 is enriched in heterochromatin and
inactive genes [13,14,15].
Recent discoveries of histone demethylases have advanced our
understanding of transcriptional regulation [16,17,18,19]. Histone
demethylases JHDM2A (also known as JMJD1A or KDM3A; new
nomenclature [20]), LSD1/KDM1 and JMJD2C/KDM4C act as
co-activators in androgen receptor (AR) signaling [17,21,22,23].
In ER signaling, LSD1 and JMJD1A/KDM2A are required for
the induction of ER target genes upon E2 stimulation. Both LSD1
and JMJD1A can demethylate H3K9me2 in the regulatory region
of ER target genes, thereby releasing the transcriptional block
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responsive cells and/or tissues in vivo is still unclear.
Abnormalities in the methylation of histones by histone
methyltransferases have been implicated in various cancers [24].
Thus, it is possible that dysregulation of LSD1 or JmjC-domain-
containing histone demethylases could contribute to tumorigene-
sis. Here we characterize JMJD2B as a newly-appointed co-
regulator of ERa signaling in breast cancer growth and mammary
gland development.
Materials and Methods
Ethics Statement
All experimental procedures were approved by the local Ethical
Committee for Animal Experimentation of Ontario Cancer
Institute (OCI), University Health Network (AUP#2031). The
research projects that are approved by the local Ethical
Committee for Animal Experimentation of OCI are operated in
accordance with applicable Federal, Provincial, Municipal and
Institutional regulations, the Policies and Guidelines of the
Canadian Council on Animal Care and the Province of Ontario’s
Animals for Research Act. The animals are housed – accordance
with applicable Federal, Provincial, Municipal and Institutional
regulations, the Policies and Guidelines of the Canadian Council
on Animal Care and the Province of Ontario’s Animals for
Research Act in the OCI Animal Facilities of the university. The
Institute is committed to the highest ethical standards of care for
animals used for the purpose of continued progress in the field of
human medicine.
Antibodies and primers
All antibodies and primers used are described in Procedure S1.
Database search for JMJD2B expression in breast cancers
The ONCOMINE database and gene microarray analysis tool,
a repository for published complementary DNA microarray data
(http://www.oncomine.org) [25,26], was searched to retrieve
information on JMJD2B mRNA expression in human breast
cancers. Statistical analysis of the differences in JMJD2B
expression between ER-positive and ER-negative breast cancers
was performed using ONCOMINE algorithms that allow for
multiple comparisons among different studies.
Cell lines and culture conditions
MCF-7 and T-47D human breast cancer cells were obtained
from American Type Culture Collection (Manassas, VA). MCF-7
cells were cultured in Eagle’s Minimum Essential Medium (ATCC
#30-2003) supplemented with antibiotics, 10% fetal bovine serum
(FBS) and 0.01 mg/mL bovine insulin. T-47D cells were cultured
in RPMI-1640 supplemented with antibiotics, 10% FBS and 0.2
units/mL bovine insulin. For steroid-free medium, phenol red-free
DMEM (Gibco) and charcoal/dextran-treated FBS (HyClone,
SH30068) were used.
Real-time RT-PCR
RNA was extracted from cells using an RNeasy Mini kit
(Qiagen). Total cellular RNA was converted into cDNA by reverse
transcription (Superscript III; Invitrogen Life Technologies) using
random primers. PCR amplification was performed using Power
SYBR Green qPCR SuperMix-UDG with ROX (Invitrogen Life
Technologies) through 40 cycles of 95uC for 15 s and 60uC for
60 s using an Applied Biosystems PRISM 7900 Sequence
Detection System.
RNA interference
siRNAs for JMJD2A and JMJD2B and non-targeted control
siRNA were purchased from Dharmacon. Validations of the
siRNAs are in Figures S1A, S1B, S1C, S1E and S1F. For JMJD2B
shRNA, the pLKO.1 puro (Addgene plasmid #8453) [27]
lentiviral vector and control scrambled shRNA (Addgene plasmid
#1864) [28] were used. Lentivirus was prepared by transfecting
293T cells with the knockdown vectors, pMD2.G (Addgene
plasmid #12259) and psPAX2 (Addgene plasmid #12260).
Target sequences are in Procedure S1.
Soft agar assay
ZR-75-1 cells, MCF-7 cells, or derivative cell lines were cultured
in 12-well plates containing a bottom agar layer consisting of
culture medium plus 0.7% agar and 2 ng/mL puromycin. The
middle layer contained 10
5 cells in culture medium plus 0.35%
agar and 1 ng/mL puromycin. Medium alone was added as the
top layer to prevent desiccation of the agarose. Colonies were
allowed to form for 14 days prior to visualization by crystal violet
staining.
Mouse Xenograft Breast Cancer Models
Slow-release estradiol pellets were implanted subcutaneously
into NIH-III mice (Crl:NIH-Lyst
bgFoxn1
nuBtk
xid, 7-week old,
Charles River Laboratories) three days before tumor transplanta-
tion. 3610
6 ZR-75-1 cells grown in cell culture were suspended in
50 mL medium, mixed with 50 mL Matrigel, and injected
subcutaneously into hind flanks. Tumors derived from injected
cells were harvested two weeks after transplantation.
BrdU/7-AAD staining
For cell cycle analysis using BrdU and 7-amino-actinomycin D
(7-AAD), cells were pulsed with 10 mM BrdU for 1 hr. The FITC
BrdU flow kit (BD Biosciences) was used to detect BrdU.
Fluoresence-activated cell sorting (FACS) analysis was performed
on a FACSCalibur (Becton Dickinson), and data were analyzed
with Cellquest or FlowJoe software.
Immunoprecipitation assay
Cells were washed with PBS, scraped off, and collected by
centrifugation. The cells were suspended in hypotonic buffer
(10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl2, 0.5%
NP-40) in the presence of protease inhibitors (Complete(R), Roche).
After washing with PBS, the pellet was resuspended in 1 mL of NP-
40 IP lysis buffer (50 mM TrisHCl (pH 7.6), 150 mM NaCl, 1%
NP-40, 1 mM EDTA) containing protease inhibitors. The lysate
was sonicated at 5% output for 20 sec. After centrifugation, the
supernatant was collected and precleared by incubating with
protein A magnetic beads (DynabeadsH, Invitrogen) at 4uC for
1 hr. Fresh protein A beads were washed with PBS-T (PBS+0.05%
Tween) three times, resuspended in 100 mL PBS-T, and incubated
with 5 mg of indicated antibodies at 4uC for 1 hr. The antibody-
coated beads were then washed with PBS-T three times and
incubated with 800 mL of the lysate at 4uC over night. The rest of
the samples were kept for INPUT. After extensive wash, the beads
weresuspended in80 mLof2 6samplebufferand boiledat95uCfor
5 min to elute associated proteins. To elute JMJD2C, the beads
were incubated with 40 mL of 8 M Urea for 15 min at 37uC, and
then boiled with 40 mLo f4 6sample buffer.
ChIP assay
Cells were crosslinked in 1% formaldehyde for 10 min at room
temperature. Cells were lysed and sonicated to obtain fragmented
JMJD2B Acts as Co-Factor of ERa
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antibodies coupled to protein A Dynabeads (Invitrogen). The
protein-DNA complexes were eluted from the beads and
incubated at 65uC overnight to reverse protein-DNA crosslinks.
Precipitated DNA was analyzed by real-time PCR. Refer to
Procedure S1 for primer information. The full version of ChIP
assay procedure is in Procedure S1.
ERa binding site analysis
Putative ER binding sites were identified by analyzing the bed files
(http://rese rch4.dfci.harvard.edu/brownlab/datasets; http://www.
ncbi.nlm.nih.gov/pubmed/19005469) using UCSC genome brows-
er. ERa responsive elements (EREs) were determined by Mapper
(http://bio.chip.org/mapper).
Gene targeting in mice
A Jmjd2b-targeting vector was constructed in which the neo
cassette was flanked by frt sequences, and Jmjd2b exon 5 was
flanked by loxP sequences (Figure S6A). Cre-mediated removal of
exon 5 results in a frameshift and translation termination, and
removal of H189 and E191 residues essential for demethylase
activity. Homologous recombination in ES cells and germ line
transmission were confirmed by Southern blot analysis (Figures
S6B abd S6C). The full version of the gene targeting strategy is
Procedures S1.
Isolation of mammary epithelial cells
Mammary fat pads were minced into paste, digested in
collagenase/hyaluronidase solution (StemCell Technologies,
07912), and dissociated with dispase (StemCell Technologies,
07913). Samples were washed with Hanks’ Balanced Salt Solution
supplemented with 2% FBS and 2 mmol/L EDTA (HFE) and
centrifuged at 3006g for 5 min. The pellet was washed with HFE
and then passed through a 40 mm cell strainer to obtain a single-
cell suspension. CD45
+Ter119
+ and CD31
+ cells were removed
using the EasySep biotin selection kit (StemCell Technologies) to
obtain Lin
2 cells.
Results
As a first step towards identifying signature differences between
ER-positive and ER-negative breast cancers, we searched the
ONCOMINE database [25–26] and found 19 suitable studies
(Table S1). In most of these studies, expression of JMJD2B mRNA
was higher in ER-positive cancers than in ER-negative cancers
(Figure 1A; refer to Table S1 for p-values). We examined protein
levels of JMJD2 family members in breast cancer cell lines.
JMJD2B expression was generally higher in ER-positive than in
ER-negative lines (Figure 1B). Furthermore, JMJD2B protein
levels increased in response to E2 treatment in the ER-positive
breast cancer cell line T-47D, but not in the ER-negative breast
cancer cell line MDA-MB468 (Figure 1C). Real-time RT-PCR
analysis confirmed that JMJD2B mRNA, but not JMJD2A or
JMJD2C mRNA, was induced upon E2 treatment (Figure 1D).
To understand the role of JMJD2B in regulating cancer cell
growth, siRNA was used to knock down JMJD2B expression in T-
47D cells (Figure S1A). At 72 hr post-siRNA transfection, we
analyzed proliferation by BrdU/7-AAD staining and flow
cytometry, and found that BrdU incorporation was substantially
reduced in JMJD2B-depleted cells but not in control cells or
JMJD2A-depleted cells (Figure 2A). To investigate the effects of
prolonged JMJD2B depletion, we generated ZR-75-1 cells in
which JMJD2B expression was knocked down using short hairpin
RNA (shRNA; Figure S1D), and assessed the ability of these cells
to form colonies in soft agar. JMJD2B-depleted ZR-75-1 cells
formed fewer and smaller colonies relative to control (Figure 2B).
Reduced colony formation was also observed for MCF-7 cells
expressing JMJD2B-targeted shRNA (Figure S2).
We performed xenograft experiments in which NIH-III mice
were subcutaneously implanted with slow-release estradiol pellets
and injected with ZR-75-1 cells expressing control shRNA and
shRNA against JMJD2B. The two cell lines were injected into
opposing flanks of the same mouse. JMJD2B-depeleted cells gave
rise to significantly smaller tumors than cells expressing control
shRNA (Figure 2C). These results demonstrate that JMJD2B
positively regulates the proliferation of ER-positive breast cancer
cell lines.
JMJD2C associates with androgen receptor and is required for
its transcriptional activity [29]. Furthermore, knockdown of
JMJD2C in prostate cancer cell lines impairs the response to
androgen receptor ligand [29]. We, therefore, speculated that
JMJD2B may be required for ER transcriptional activity. We co-
transfected 293T cells with MYC-tagged ERa and FLAG-tagged
JMJD2B, and observed that JMJD2B co-immunoprecipitated with
ERa (Figure 3A). We then generated a series of FLAG-tagged
JMJD2B mutant proteins bearing carboxy-terminal deletions
(Figure 3B) and tested them for co-immunoprecipitation with
ERa. The JMJD2B protein contains N-terminal JmjN and JmjC
domains, a central Pro-rich domain, and C-terminal double PHD
and double Tudor domains (Figure 3B). We found that only the
JmjC domain was required for the interaction with ERa
(Figures 3C and S3D). We then tested whether ERa interacts
with a catalytically inactive JMJD2B mutant (DFeJMJD2B; Figure
S3F) which contains point mutations (H189Y and E191A) in the
iron-binding region [30,31,32,33]. The data suggest that catalytic
activity of JMJD2B does not affect the interaction with ERa
(Figure S3A). We found that the benzonase treatment did not
influence the interaction between ERa and JMJD2B (Figures S3B
and S3C). These data demonstrate that the ERa-JMJD2B
interaction is DNA independent.
Given that the JmjC domain of JMJD2B mediates the
interaction with ERa and that the JmjC domain is conserved
among JMJD2 proteins, it is possible that JMJD2A and JMJD2C
also interact with ERa. To address this issue, nuclear proteins
were extracted from T-47D cells and co-immunoprecipitation
experiments were performed with antibodies specific to endoge-
nous proteins. Antibodies to JMJD2A or JMJD2B immunopre-
cipitated a substantial amount of ERa. In contrast, complexes
between JMJD2C and ERa appeared to be less abundant
(Figure 3D). We also performed co-immunoprecipitation assay
for the extracts treated with benzoase.
ERa recruits the SWI/SNF chromatin remodeling complex
(BAF complex) to target genes upon estrogen stimulation. We
found that JMJD2A, JMJD2B, and JMJD2C interacted with one
of the core subunits of SWI/SNF complex, BRG1 ATPase
(Figure 3D). JMJD2A and JMJD2B also interacted with Poly-
bromo1 but not ARID1B, whereas JMJD2C interacted with
ARID1B and, to a lesser extent, Polybromo1 (Figure 3D). Because
Polybromo1 is specific to the SWI/SNF-B complex (P-BAF
complex) and ARID1B is specific to the SWI/SNF complex,
these results suggest that JMJD2A and JMJD2B associate
specifically with the SWI/SNF-B complex whereas JMJD2C
associates preferentially with the SWI/SNF complex. We further
examined whether formation of these JMJD2B-containing com-
plexes is estrogen dependent. Estrogen treatment resulted in
nuclear accumulation of ERa and an increased association
between ERa and JMJD2B (Figures 3E and S3E). In contrast,
estrogen stimulation did not affect the interaction between
JMJD2B Acts as Co-Factor of ERa
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aJMJD2B and subunits of the SWI/SNF complex (Figures 3E and
S3E), suggesting that JMJD2B can interact with the SWI/SNF-B
complex in the absence of estrogen stimulation. We could not
detect an interaction between JMJD2B and p300 (Figure 3E)
which is supposedly recruited to ERa with kinetics distinct to those
of the SWI/SNF complex [7].
We next assessed whether JMJD2B is required for activation of
ER target genes. Induction of GREB1 in response to E2 was
significantly reduced in JMJD2B-depleted T-47D cells and
JMJD2B-depleted MCF-7 cells but not in JMJD2A-depleted cells
(Figure 4A). MYB oncogene is an ER target gene and required for
ER-induced cell proliferation [34]. The induction of MYB in T-
47D cells and MCF-7 cells was impaired by JMJD2B knockdown,
whereas JMJD2A knockdown impaired MYB induction to a
modest degree (Figure 4A). These results are consistent with the
observation that knockdown of JMJD2A had little effect on the
proliferation of T-47D cells (Figure 2A). Collectively, these results
indicate that JMJD2B is required for the full extent of ERa
transcriptional activity and that the JMJD2A has only a limited
role in the transcriptional activity of ERa despite a comparable
affinity for ER and SWI/SNF-B complexes. Therefore, we focused
our attention on the function of JMJD2B. Induction of other ER
Figure 1. Elevated expression of JMJD2B in ER-positive breast cancers. (A) JMJD2B mRNA expression in clinical breast cancer samples from
19 studies registered in the ONCOMINE database. Blue bars, JMJD2B mRNA in ER-negative samples; red bars, JMJD2B mRNA in ER-positive samples.
Data were analyzed using ONCOMINE algorithms. mRNA expression levels are represented by normalized units. The line within each colored box
represents the median value for each group, and the upper and lower edges of each box indicate the 75th and 25th percentiles, respectively. Study
details and statistical values are described in Table S1. (B) JMJD2B protein levels are higher in ER-positive breast cancer cell lines. Extracts of ER-
positive and ER-negative breast cancer cell lines were analyzed by western blot to detect JMJD2 family members. Actin, loading control. (C) JMJD2B
protein expression is induced by E2 stimulation. T-47D cells (ER-positive) and MDA-MB468 cells (ER-negative) were cultured in steroid-depleted serum
for 4 days and stimulated with or without E2 for 24 hr. Cell extracts were analyzed by western blot. Relative intensity of the JMJD2A and JMJD2B
bands are shown. The values are normalized to the bands of corresponding actin. (D) E2 stimulates JMJD2B expression. T-47D cells were cultured in
steroid-depleted serum for 4 days followed by E2 stimulation for 6 hr. JMJD2A, JMJD2B and JMJD2C transcript levels are shown relative to levels in
untreated controls (set to a value of 1). Expression levels were normalized to ACTB expression levels. Data represent mean 6 s.d. of triplicates.
** p,0.01. Full-length blots are presented in Figure S7.
doi:10.1371/journal.pone.0017830.g001
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in JMJD2B-depleted T-47D cells (Figure 4B) and JMJD2B-
depeleted MCF-7 cells (Figure S4A).
To further assess the effect of JMJD2B depletion, we performed
genome-wide gene expression analysis using the Affymetrix
Human Gene 1.0 ST array. RNA was extracted from steroid-
depleted control MCF-7 cells (control E2(2)), control MCF-7 cells
treated with E2 (control E2(+)), steroid-depleted JMJD2B-depleted
MCF-7 cells (siJ2B E2(2)), and JMJD2B-depleted MCF-7 cells
treated with E2 (siJ2B E2(+)). After normalizing the data, we
identified genes that exhibited a log-fold change of greater than 2
between control E2(2) and control E2(+) cells, or between control
E2(+) and siJ2B E2(+) cells. (The false discovery rate (FDR) was set
at ,0.05.) In total, we identified 1432 differentially expressed
genes (Figures 4C and S4C; Table S2, S3, S4). 878 genes were up-
regulated or down-regulated by JMJD2B knockdown, but not
affected by E2 stimulation. These genes represent candidate
JMJD2B target genes that are independent of ER signaling. 360
genes were induced by E2, whereas 194 genes were down-
regulated by E2. Among these 360 genes, 53 genes (14.7%) were
down-regulated in siJ2B E2(+) relative to control E2(+) cells
(Figure 4C), indicating that a subset of E2-induced genes were
dependent on JMJD2B for full induction. Again we observed
impaired induction of MYB, GREB1, and BCL2 in JMJD2B-
depleted cells (Figure S4B), although the changes in transcript
levels did not pass the criteria of ,0.05 FDR and .2 log-fold
difference.
To determine whether JMJD2B is required for cellular
responses to estrogen, we stimulated JMJD2B-depleted T-47D
and MCF-7 cells with E2 and measured BrdU incorporation at
72 hr post-transfection. E2 stimulated the proliferation of control
cells but had a limited effect on the proliferation of JMJD2B-
depleted cells (Figures 4D and S4D), indicating that JMJD2B is
required for the proliferative response to estrogen. Since the
induction of MYB, MYC, and CCND1 genes were reduced in
JMJD2B-depleted cells upon E2 treatment, impairment of G1/S
Figure 2. JMJD2B positively regulates the proliferation of ER-positive breast cancer cells. (A) JMJD2B knockdown impairs proliferation. T-
47D cells were transfected with either control siRNA or siRNA against JMJD2A or JMJD2B, cultured for 72 hr, pulsed for 1 hr with BrdU, stained with
APC-conjugated anti-BrdU antibody and 7-AAD, and analyzed by flow cytometry. Results are representative of four independent trials. (B) JMJD2B
knockdown impairs colony formation. Single cell suspensions of ZR-75-1 cells expressing control shRNA or shRNA against JMJD2B were seeded in soft
agar. After 14 days, colonies were stained with crystal violet and microscopic fields were photographed (left). The number of colonies/cm
2 was
determined (right). Data represent the colony density of three wells (mean 6 s.d). **p,0.01. Representative data of three independent trials. See also
Figure S2. (C) JMJD2B knockdown impairs tumor formation in xenograft model. Upper left: tumors (indicated by arrows) in a representative NIH-III
mouse injected with control ZR-75-1 cells on the left flank and JMJD2B-depleted ZR-75-1 cells on the right flank. Upper right: dissected tumors from
nude mice. Lower: mass of tumors is shown. **p,0.01.
doi:10.1371/journal.pone.0017830.g002
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been recently reported that JMJD2B-depletion also influences
genes required for G2/M transition [35].
We next analyzed the interaction of ERa with target gene loci
by performing chromatin immunoprecipitation (ChIP). We
selected candidate ER binding sites according to the results of a
published genome-wide analysis [36] and confirmed the binding of
ERa to ER target genes including MYB, JMJD2B, and GREB1
(Figure 5A). Recently, it has been reported that most estrogen
receptor binding sites are distal to transcription start sites (TSSs).
Indeed, ER binds to MYB and GREB1 loci more than 20 kb
downstream of their respective TSSs (Figure S5A). The interaction
of ERa with these sites increased 45 min after E2 stimulation and
then declined 4 hr later (Figure 5A). We also observed marked
increase of JMJD2B binding to these sites following E2 stimulation
(Figure 5A). Notably, ERa and JMJD2B were both detected at the
ERa binding site in the JMJD2B locus, suggesting that JMJD2B
regulates itself at the transcriptional level in concert with ERa,
which is consistent with the previous genome wide analysis of ERa
binding site [37].
We next addressed the demethylation of H3K9me3 at ER
binding sites. We observed decreased H3K9me3 at ER binding
sites following E2 stimulation in control but not in JMJD2B-
depleted T-47D cells (Figure 5B), suggesting that JMJD2B
regulates the demethylation of H3K9me3 at ER binding sites.
H3 enrichment at MYB ERE appears to decrease over the time
after E2 addition but H3 displacement during the time window we
have analyzed is not statistically significant whereas H3K9me3/
H3 ratio at MYB ERE decreases to approximately one-third in the
presence of E2 (Figure S5C). We also examined RNA polymerase
II (RNAPII) levels at upstream of the ER binding site in MYB
gene. The RNAPII levels were markedly increased in control
T47D cells in response to E2 treatment. Conversely, the induction
of RNAPII levels was significantly impaired in JMJD2B-depleted
cells (Figure 5C). These findings further support a role of JMJB2B
in ER regulated transcription.
Figure 3. JMJD2B interacts with ERa and SWI/SNF-B complex. (A) JMJD2B co-immunoprecipitates with ERa. 293T cells were co-transfected
with expression plasmids for FLAG-JMJD2B and either MYC-ERa or empty vector. Cell lysate and a-MYC immunoprecipitates were analyzed by
western blot with a-FLAG antibody. (B) Structure of JMJD2B deletion mutants. Pro rich, proline rich region. LRPLL, LRPLL motif. PHDx2, double PHD
domain. TUDORx2, double TUDOR domain. Western blot analysis of mutants is shown in Figure S3A. (C) The JmjC domain is sufficient for co-
immunoprecipitation with ERa. 293T cells were co-transfected with MYC-ERa and individual JMJD2B deletion mutant expression vectors (refer to B).
Cell lysates and a-FLAG immunoprecipitates were analyzed by western blot with antibodies to the indicated proteins. Relative intensity of the bands
of the mutants is shown, normalized to the bands of corresponding input. Arrowheads, ERa bands; *, a-FLAG antibody. (D) Association of JMJD2
proteins with ERa, SWI/SNF complex, or SWI/SNF-B complex. (E) Association of JMJD2B with ERa or SWI/SNF-B complex in the absence or presence of
estrogen simulation. (D and E) Nuclear lysates of T-47D cells were immunoprecipitated with control IgG or antibodies to the indicated proteins. Input
lysate and immunoprecipitated samples were immunoblotted using antibodies to the indicated proteins. See also Figure S3. Full-length blots are in
Figure S7.
doi:10.1371/journal.pone.0017830.g003
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JMJD2A or JMJD2B knockdown on induction of ER target genes. T-47D cells and MCF-7 cells were transfected with either control siRNA, JMJD2A
siRNA or JMJD2B siRNA, cultured in steroid-free medium for 72 hr, and stimulated with or without E2 for 4 hr. (B) JMJD2B knockdown impairs ER
target gene induction. T-47D cells were transfected with either control siRNA or JMJD2B siRNA, cultured in steroid-free medium for 72 hr, and
stimulated with or without E2 for 4 hr. (A and B) mRNA levels of JMJD2B or the indicated ER target genes were measured by real-time RT-PCR. Results
represent mRNA levels normalized to the level of ACTB mRNA (mean 6 s.d. of triplicates). **p,0.01. (C) Venn diagram representation of the
differentially expressed genes. The area of each circle reflects the number of genes contained in the respective categories. The heat map is in Figure
S4C. The lists of the genes are in Tables S2, S3, S4, S5. (D) JMJD2B knockdown impairs cellular response to estrogen. T-47D cells or MCF-7 cells
transfected with control siRNA or JMJD2B siRNA were cultured in steroid-free medium for 48 hr, stimulated for 24 hr with E2, labeled for 1 hr with
BrdU, and stained with anti-BrdU antibody and 7-AAD. The fraction of BrdU-positive cells was determined by flow cytometry. A representative result
from three independent experiments.
doi:10.1371/journal.pone.0017830.g004
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PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e17830To further study the involvement of JMJD2B in the demeth-
ylation of H3K9me3 at an ER target gene [34], we performed
ChIP on 12 regions within MYB locus. Loading of ERa occurred
almost exclusively at the region identified above (Figure 5D). In
control T-47D cells, H3K9me3 levels were reduced following E2
treatment at several regions of the MYB locus, including the ER
binding site. In contrast, chromatin-bound H3K9me3 was not
reduced in JMJD2B-depleted cells (Figure 5D). We also performed
ChIP for ERa. We found that JMJD2B depletion reduced ERa
enrichment (Figure 5D), suggesting that JMJD2B depletion
reduces recruitment of ERa or stability of ERa complex.
Taken together, in response to E2 stimulation, JMJD2B is
recruited to the ER binding site and demethylates H3K9me3 in
the surrounding region, thus facilitating gene induction. In some
cases, levels of chromatin-bound H3K9me3 were higher in
JMJD2B-depleted cells (Figure 5B and 5D). Histone methyltrans-
ferases has been proposed to associate with ERa to establish a
basal repressive state at ER targets [21]. It is possible that the
increase in H3K9me3 levels was caused by the loss of the
competing demethylase activity of JMJD2B.
To determine whether JMJD2B is required for the proliferation
of normal epithelial cells under physiological conditions, we
generated mice carrying a conditional allele of Jmjd2b that can be
removed in mammary epithelial cells (MECs) by expression of Cre
recombinase under the control of the MMTV promoter
(Jmjd2b
flox/flox;MMTV-Cre mice; Figure S6). We chose to flank
Jmjd2b exon 5 with loxP sequences because this exon encodes a
fragment containing H189 and E191 residues that are essential for
iron-binding and demethylase activity [30,31,32,33]. We analyzed
whole-mount specimens of mammary fat pads and noticed that
mammary gland development was delayed in Jmjd2b
flox/flox;
MMTV-Cre mice (Figure 6A). Relative to control mice,
Jmjd2b
flox/flox;MTV-Cre mice exhibited reduced branching in the
mammary gland (Figure 6A), which is consistent with a previous
report that ERa is required for ductal morphogenesis [38].
We next examined gene expression in isolated MECs. We
isolated CD45-Ter119-CD31- (Lin2) MECs [39,40,41], and
found that mRNA levels of Myb, CyclinD1 and c-myc were
significantly reduced in Jmjd2b
flox/flox;MMTV-Cre mice compared
to Jmjd2b
flox/flox mice (Figure 6B). These data further support that
the defective mammary gland development is due to the
impairment of the ER target genes induction. However, further
study is required to clarify whether Jmjd2b-deficiency primarily
leads to cell proliferation defect, apoptosis, or both.
To further assess impact of Jmjd2b-deficiency on proliferation of
MECs, the isolated Jmjd2b
flox/flox MECs were infected with either
Mock-GFP (control) or iCre-IRES-GFP retrovirus, and then
cultured in vitro. Western blotting confirmed that Jmjd2b protein
was absent from cells infected with Cre-expressing virus (Figure 6C).
FACS was used to monitor the fraction of GFP-positive cells. The
proportion of GFP-positive control cells did not change over time,
whereas that of iCre-infected, GFP-positive cells gradually
decreased, suggesting a role for Jmjd2b in the proliferation of
mammary epithelial cells (Figure 6D).
It is noteworthy that we have obtained viable Jmjd2b2/2 mice
without gross abnormalities (data not shown), indicating that
Jmjd2b is not a general regulator of cell proliferation. These
observations further support our findings that Jmjd2b has tissue
and signal specific functions.
Discussion
Intensive studies of how nuclear receptors transmit ligand
binding signals have identified several distinct multiprotein
complexes. These complexes are recruited to promoters and
enhancers, and modulate higher-order chromatin and nucleoso-
mal structures leading to activation or repression of target genes.
Genome-wide analysis of ERa binding sites has been performed
by numerous groups and potential ERE sites have been mapped in
promoter, enhancer and intronic regions; however, how the distal
regulatory EREs function and what are co-factors at these sites
remain to be elucidated.
Here, we describe indispensable roles for an H3K9 histone
demetylase, JMJD2B, in ER signaling. JMJD2B was required for
the full induction of ER target genes that function in cell
proliferation and survival pathways (Figure 4). Consequently,
inactivation of JMJD2B severely impaired the growth of ER-
positive breast cancer and development of normal breast tissues in
vivo (Figures 2 and 6). These findings are consistent with a recent
report that JMJD2B depletion causes decrease in cell proliferation
and colony formation capacity of ER-positive breast cancer cells
[35].
Further, our studies address the mechanisms by which JMJD2B
acts as a co-regulator in ER signaling. We observed that once
ligand-bound ERa translocated to the nucleus, JMJD2B was
recruited to distal ER binding sites of target genes concomitant
with a decrease in chromatin-bound H3K9me3 levels (Figure 5).
In agreement with these findings, depletion of JMJD2B severely
impaired the demethylation of H3K9me3 in ER-binding regions
upon E2 treatment (Figure 5). In addition to ERa, JMJD2B also
associated with members of a chromatin remodeling complex,
SWI/SNF-B, which is required for transactivation by nuclear
receptors [42]. We therefore propose a model in which JMJD2B at
ER binding sites removes the repressive histone marks, which may
also set up docking sites for enzymes and transcription factors that
remodel chromatin or otherwise modify gene-control regions.
Diversity among JMJD2 family proteins
Recent studies have found that JMJD2 family proteins can
target methylated H3K9 and H3K36 with some target specificity
[43], suggesting that JMJD2 members have both common and
distinct biological functions. Biochemically, JMJD2A/KDM4A
and JMJD2C/KDM4C can demethylate H3K9me3 and
H3K36me3 [33,43,44], whereas JMJD2B/KDM4B is likely more
Figure 5. JMJD2B is recruited to the ER binding site; H3K9me3 is demethylated at the ER binding site. (A) Chromatin
immunoprecipitation (ChIP) assay of ERa and JMJD2B at indicated gene loci. T-47D cells were steroid-depleted for 96 hr and treated with E2 for
45 min or 4 hr. mRNA levels of JMJD2B and the indicated ER target genes in the corresponding samples are in Figure S5B. (B) ChIP assay of H3K9me3
at indicated gene loci. T-47D cells expressing control shRNA or shRNA against JMJD2B were steroid-depleted for 96 hr and treated with E2 for 4 hr.
Results were normalized to input values, and expressed relative to untreated controls (set at 1). (C) ChIP assay of RNAPII in MYB gene. T-47D cells
expressing control shRNA or JMJD2B shRNA were treated as in (B). Results were normalized to input values, and expressed relative to untreated
controls (set at 1). (D) Presence of ERa and H3K9me3 within the MYB locus in T-47D cells. A region previously shown to be devoid of ERa was chosen
as a negative control site (ER-neg) [36]. Cells were treated as in (B). H3K9me3 ChIP signals were normalized to input chromatin and expressed relative
to ChIP signals of the negative control site (set at 1). X-axis represents distance from TSS. (A–C) ChIP samples were quantified by real-time PCR. Data
represent mean 6 s.d. of triplicates. Representative data from three independent trials. **p,0.01; *p,0.05. ER binding sites assessed in this study are
shown in Figure S5.
doi:10.1371/journal.pone.0017830.g005
JMJD2B Acts as Co-Factor of ERa
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17830specific for H3K9me3 in vitro [43] although overexpression of
JMJD2B demethylates H3K36me3 in cells [31]. Functionally,
JMJD2A regulates the balance of H3K9me3 and H3K36me3
required for maintaining genomic stability in germ cells [43].
JMJD2B has been shown to antagonize H3K9me3 at heterochro-
matin [31]. JMJD2C promotes AR signaling [29]. Our data
identify a specific role for JMJD2B in ER signaling. Among the
JMJD2 family members we tested, JMJD2A and 2B exhibited
robust interactions with ER (Figure 3); however, in contrast to
depletion of JMJD2B, depletion of JMJD2A caused only a
marginal defect in ER target gene induction (Figure 4).
JMJD2A and JMJD2B, although expressed, were not found to
be involved in AR signaling [29]. Our data strongly suggest that
JMJD2C (SWI/SNF-A) and JMJD2B (SWI/SNF-B) associate with
different remodeling complexes. Estrogen may also further
enhance JMJD2B expression to drive the vicious cycle. These
findings might explain the specificity of ligand-receptor signaling
and the mutually exclusive pathological implications involving
Figure 6. Conditional deletion of Jmjd2b in mammary epithelium results in defective mammary gland development. (A) Defective
development of Jmjd2b-deficient mammary gland. Carmine-stained whole-mount preparations of mammary glands from 5-week old
Jmjd2b
flox/flox;MMTV-Cre and Jmjd2b
flox/flox mice (Ctrl:control). Representative littermates are shown. LN, lymph node. The numbers of branching
and terminal end buds within a fat pad were determined (Jmjd2b
flox/flox n=11; MMTV-Cre;Jmjd2b
flox/flox: n=6). (B) Impaired gene expression in
Jmjd2b
flox/flox; MMTV-Cre MECs. Lin
2 MECs were isolated from Jmjd2b
flox/flox;MMTV-Cre and Jmjd2b
flox/flox mice. mRNA levels of Jmjd2b, Myb, CyclinD1
and c-myc were examined by real-time RT-PCR. Results represent mRNA levels normalized to the level of Actb mRNA (mean 6 s.d. of five independent
littermate pairs). (C) Western blot showing the absence of Jmjd2b protein in Cre-infected Jmjd2b
flox/flox MECs. Full-length blots are in Figure S7 (D)
Impaired proliferation of Jmjd2b-deficient MECs. Lin
2 MECs were isolated from Jmjd2b
flox/flox mice, infected with Mock-GFP or Cre-IRES-GFP (iCre-GFP)
retrovirus, and cultured in vitro. Fractions of GFP-positive cells were determined at the indicated time points by FACS analysis. A representative result
from three independent experiments is shown.
doi:10.1371/journal.pone.0017830.g006
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elucidate the signal and target specificity of each JMJD2 family
member.
Roles of histone lysine methylation in ER signaling
Genome-wide ChIP analysis of ER binding regions [36,37,45]
and ChIP-sequence studies of RNAPII recruitment [46,47] have
revealed that, in addition to ERa binding, modifications of local
chromatin and epigenetic states, recruitment of specific co-factors
and release of RNAPII pausing are critical for the transcriptional
regulation of ER responsive genes.
Enrichment of H3K9me3 has been reported in coding regions
of some active genes [48,49]; however recent genome-wide
investigations support the general repressive nature of the
H3K9me3 mark [13,15]. Increasing recent evidence indicates
that genomic architecture is not colinear but is modular [50], and
permissive and repressive chromatin regions exist within the body
of gene. The intragenic permissive chromatin regions are flanked
by the repressive mark, H3K9me3, and the maintenance of the
intragenic chromatin boundary appear to functions as a
checkpoint in elongation [51]. We observed enrichment of
H3K9me3 near the distal ER binding site under steroid-depleted
condition, and found that the methylation levels significantly
decreased upon E2 stimulation in a JMJD2B dependent manner
(Figures 5B and 5D). In addition, JMJD2B-depletion reduced
RNAPII occupancy (Figure 5C). Thus, our data suggest that
JMJD2B contributes the establishment of local epigenetic state and
chromatin structure, which are required for proper induction of
ER responsive genes.
We observed the binding of ERa and JMJD2B to ER binding
regions in the absence of estrogen stimulation although the
binding increased upon estrogen stimulation (Figure 5A). LSD1
and JMJD2C have been shown to present at promoter and
enhancer regions of AR-dependent genes prior to ligand
stimulation. However, ligand-receptor interaction is needed to
induce AR recruitment and subsequent demethylation [22,29]. In
an analogous way, recruitment of liganded ER and other co-
factors may be necessary for JMJD2B activity. Further genome-
wide analysis will be required to clarify these issues.
Biological significances of JMJD2B in human diseases
Recent studies have implicated H3K9 modifications in
numerous biological phenomena including germ cell development,
X chromosome inactivation, DNA damage repair and apoptosis
[14]. Recent reports also link deregulated histone methylation to
tumorigenesis [52,53].
Interestingly, focal amplification of JMJD2B locus was
identified in brain tumors [54]. An H3K9 histone methyltrans-
ferase, Suv39H1, has been shown to function as a tumor
suppressor by maintaining H3K9 methylation levels [55,56]. In
addition, we show that JMJD2B enhances the transcriptional
activation of oncogenes and anti-apoptotic genes. Dysregulation
of JMJD2 thus may counteract the tumor suppressive function of
Suv39H1.
In conclusion, our data indicate that JMJD2B regulates an
epigenetic signature in ER binding regions distal to TSSs leading
to the establishment of specific transcriptional programs and
biological effects downstream of ER signaling. In addition, the
recent report has identified that combination of expression levels
of a hypoxic marker and JMJD2B predict patient survival [35].We
thus believe that further characterization of JMJD2B and related
signaling components may identify therapeutic targets and
prognostic markers for human cancers.
Supporting Information
Figure S1 Validation of JMJD2B knockdown efficiency.
(A) T-47D cells were transfected with siRNA against JMJD2A
(target sequences #1 and #2). (B) T-47D cells were transfected
with siRNA against JMJD2B (target sequences #1, #2, and #6).
(A and B) Total cell lysate was prepared 72 hr after transfection
and subjected to western blotting. (C) T-47D cells were transfected
with si JMJD2B #1o r#2. RNA was extracted 72 hr after
transfection and subjected to quantitation by real-time RT-PCR.
(D) MCF-7 cells were infected with a lentiviral vector harboring
JMJD2B shRNA targeting sequence #1, #2o r#3. Total cell
lysates were prepared 48 hr after infection and subjected to
western blotting. (E) T-47D cells were transfected with siRNA
against JMJD2B (target sequences #1, #2, and #6). Total cell
lysate was prepared 72 hr after transfection and subjected to
western blotting for JMJD2A. The introduction of #6 siRNA
reduced JMJD2A protein levels. We therefore used #1 and #2
siRNA in this study. Positive control: protein samples from
JMJD2A overexpressed cells. (F) T-47D cells were transfected with
siRNA against JMJD2A (target sequences #1, #2, #3 and #4).
Total cell lysate was prepared 72 hr after transfection and
subjected to western blotting for JMJD2B.
(TIF)
Figure S2 JMJD2B knockdown decreases colony forma-
tion of MCF-7 cells. Single cell suspensions of MCF-7 cells
expressing control shRNA or shRNA against JMJD2B (target
sequence #2) were seeded in 0.35% soft agar. After 14 days,
colonies were stained with crystal violet. Microscopic fields were
photographed (left). The number of colonies/cm
2 was determined
(right). Data are the mean number of colonies formed in three
wells 6 s.d., p,0.01. A representative result from four
independent trials.
(TIF)
Figure S3 JMJD2B interacts with ERa and SWI/SNF-B
complex. (A) Catalytic activity of JMJD2B does not influence the
interaction with ER. 293T cells were co-transfected with MYC-
ERa and either empty vector, FLAG-JMJD2B or FLAG-
DFeJMJD2B (a mutant with (H189Y and E191A) point mutations
in the iron-binding region). a-MYC immunoprecipitates were
analyzed by western blot with a-FLAG antibody. (B) Benzonase
treatment does not affect the interaction of endogenous JMJD2B
and ER. Nuclear lysates of T-47D cells were lyzed and sonicated
in the presence or absence of 500 unit of Benzonase (Novagen)
before immunoprecipitation with a-JMJD2B Ab. Input lysate and
immunoprecipitated samples were immunoblotted using a-ERa
antibody. Full-length blots are presented in Figure S7. (C)
Sonication and benzonase treatment digest genomic DNA.
Nuclear lysates were treated as in (B). 15% of treated and
untreated samples applied for immunoprecipitation were loaded
on 0.8% gel. The arrow indicates undigested genomic DNA. (D)
The JmjN and JmjC domains are sufficient for co-immunopre-
cipitation with ERa. 293T cells were co-transfected with MYC-
ERa and one of several JMJD2B deletion mutant expression
vectors encoding the structures illustrated in Figure 3B. Cell lysates
and a-FLAG immunoprecipitates were analyzed by western blot
with antibodies against the indicated proteins. Relative intensity of
the bands of the Flag-JMJD2B and mutants are shown,
normalized to the bands of corresponding input. The values are
presented wild type as 1. Arrowheads, ERa bands; arrows, wild
type or deletion mutant JMJD2B proteins; asterisk, a-FLAG
antibody. (E) Kinetics of Association between JMJD2B and ERa
JMJD2B Acts as Co-Factor of ERa
PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e17830or SWI/SNF-B complex. Nuclear lysates were harvested at
indicated time points after E2 stimulation and subjected to
immunoprecipitation with control IgG or the antibodies against
the indicated proteins. Input lysate and immunoprecipitated
samples were then immunoblotted using antibodies against the
indicated proteins. (F) JMJD2B reduces H3K9me3 levels. U2OS
cells were transfected with FLAG-JMJD2B and FLAG-
DFeJMJD2B and stained with anti-FLAG and anti-H3K9me3
antibodies followed by anti–mouse IgG (green) or anti–rabbit IgG
(red). Nuclei were visualized using Hoechst 33258. Overlay: merge
of FLAG and H3K9me3 staining. Data shown are representative
of two independent preparations.
(TIF)
Figure S4 JMJD2B mediates induction of ER target
genes and estrogen-dependent proliferation of breast
cancer cells. (A) JMJD2B is required for the induction of ER
target genes. MCF-7 cells were transfected with either control
siRNA or JMJD2B siRNA (target sequence #1), cultured in
steroid-free medium for 72 hr, and stimulated with or without E2
for 4 hr. mRNA levels of JMJD2B or the indicated ER target
genes were measured by real-time RT-PCR. Results shown are
mean mRNA level normalized to the amount of ACTB mRNA 6
s.d. of triplicates. **, p,0.01. (B) Microarray data for represen-
tative ER target genes. Signal intensities on microarray for
representative ER target genes are shown by their mean values
(6SD). (C) Heat map representation of differentially expressed
genes. One thousand four hundred and thirty-two differentially
expressed genes (as calculated using a false discovery rate ,0.05
and log-fold change .2) were sorted by hierarchical clustering.
Each row represents a gene and each column represents a sample.
Red indicates higher expression and blue lower expression. (D)
JMJD2B knockdown impairs cellular response to estrogen. T-47D
cells or MCF-7 cells transfected with control siRNA or JMJD2B
siRNA were cultured in steroid-free medium for 48 hr, stimulated
for 24 hr with E2, labeled for 1 hr with BrdU, and stained with
anti-BrdU antibody and 7-AAD. The fraction of BrdU-positive
cells was determined by flow cytometry. A representative result
from three independent experiments.
(TIF)
Figure S5 ER binding sites assessed in this study. (A)
The UCSC Genome browse map depicts the ER binding sites of
MYB locus, JMJD2B locus, and GREB1 locus. Depicted ER
binding sites are identified in previously published studies. (B)
Effect of JMJD2B knockdown on induction of ER target genes.
mRNA levels of JMJD2B or the indicated ER target genes in the
corresponding samples applied for the ChIP analysis are shown.
(C) The change of H3 and H3K9me3/H3 ratio at Myb ERE.
(TIF)
Figure S6 Conditional gene targeting of murine Jmjd2b
locus. (A) Introduction of loxP sites into Jmjd2b. A portion of the
murine wild type Jmjd2b locus showing exon 5 (grey rectangle) and
an 11.9 kb XbaI fragment are shown at the top. The targeting
vector was designed to generate floxed exon5 (loxP; black
triangles), to flank the PGK-neo cassette with frt sequences (grey
triangles), and to introduce a new XbaI site (X). The targeted allele
contains a diagnostic 7.7 kb XbaI fragment. The neo cassette was
removed in vivo by FLPe recombinase as described in Materials
and Methods. Cre-mediated recombination resulted in the
deletion of Jmjd2b exon 5. The position of the 59 flanking probe
used for genotyping is indicated. (B) Southern blot analyses to
identify Jmjd2b
neo/+ ES cells (lanes 2, 4, 5, and 6). Genomic DNA
was digested with XbaI (upper panel) or EcoRI (lower panel) and
hybridized with the probe indicated in (A). (C) Southern blot
analyses to identify Jmjd2b
neo/+ mice (lanes 2 and 3), Jmjd2b
flox/+
mice (lanes 4 and 5), and Jmjd2b
+/D mice (lanes 6 and 7). Genomic
DNA was digested with XbaI (upper panel) or EcoRI (lower panel)
and hybridized with the probe indicated in (A). The numbers in
brackets indicate the ES clones from which the mice were derived.
(TIF)
Figure S7 Full-length blots images. Full-length blot images
related to Figures 1, 3, S3 and 6 are shown. The cropped regions
are indicated.
(TIF)
Table S1 P value of difference in JMJD2B mRNA
expression in ER-positive and ER-negative breast can-
cers in 19 ONCOMINE studies.
(DOC)
Table S2 Genes down regulated in JMJD2B depleted
cells.
(XLS)
Table S3 Genes upregulated in JMJD2B depleted cells.
(XLS)
Table S4 Genes down regulated in E2 treated JMJD2B
depleted cells.
(XLS)
Table S5 Genes upregulated in E2 treated JMJD2B
depleted cells.
(XLS)
Procedure S1
(DOC)
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